Insider Sale at Achillion Pharmaceuticals (ACHN) Deemed Significant

Wednesday, November 22, 2017 10:15 PM ET

Insider Sale at Achillion Pharmaceuticals (ACHN) Deemed Significant

One insider — & Johnson, 10% Owner — today, sold 18,367,346 shares of Achillion Pharmaceuticals having a market value of approximately $50,510,202, as disclosed in a form 4 document filed with the SEC. This is the first insider buy/sell trade in the past 90 days.

Achillion Pharmaceuticals level of buy-sell trading activity is close to the 272 member peer company average. The Bio Therapeutic Drugs peer group saw 335 buy/sell trades during this period for an average of 1.2 transactions per company. However, the number of shares per buy/sell trade transacted by Achillion Pharmaceuticals insiders is higher. Within the peer group there were 37,220,290 shares purchased and 21,408,033 shares sold with company insiders having bought 76,759 shares on average.

Significant insider buying and selling activity has been determined by eliminating all trading activity reported to the SEC that involves awards, options, exercise of derivative securities, company buy-backs, taxes, gifts, shares acquired via inheritance and tenders or exchange offers in data sourced in creating and writing this story.

Using proprietary Natural Language Generation (NLG) technology, UpTick evaluates corporate insider filings reported to the SEC and creates real-time news and analysis to report the most significant insider transactions based on transaction type, size and historical trends.

For more information, contact UpTick at info@uptickdata.com. Copyright 2017 UpTick Data Technologies. All rights reserved.

This entry was posted in InsiderNews and tagged , , , , . Bookmark the permalink.